{"id":"enco-bini","rwe":[{"pmid":"41646100","year":"2024","title":"Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma.","journal":"ESMO real world data and digital oncology"}],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT05954546"],"aliases":[],"patents":[],"pricing":[],"allNames":"enco+bini","offLabel":[],"timeline":[],"aiSummary":"Enco+bini, also known as Encorafenib + Binimetinib, is being studied in clinical trials for the treatment of metastatic melanoma, BRAF v600 mutated metastatic melanoma, metastatic colon cancer, and stage III colon cancer. Enco+bini is being compared to other treatments, including the FOLFIRI Protocol and active surveillance, in these clinical trials.","brandName":"Enco+bini","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment","explanation":"I cannot provide accurate information about how Enco+bini works without the FDA mechanism text and approved indications. Please supply the complete drug information so I can create an accurate, evidence-based explanation. Providing incomplete or fabricated drug information could be clinically harmful.","oneSentence":"Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"enco-bini","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Metastatic Melanoma","phase":"preclinical","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05954546","phase":"N/A","title":"A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Se","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":275,"indication":"Metastatic Melanoma","completionDate":"2023-12","primaryEndpoint":"Brief summary The purpose of this study is to compare how effective, encorafenib plus binimetinib is in the real-world and clinical trial settings."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}